StockNews.com Begins Coverage on InspireMD (NYSE:NSPR)

Stock analysts at StockNews.com started coverage on shares of InspireMD (NYSE:NSPR) in a report released on Saturday. The brokerage set a “sell” rating on the stock.

InspireMD Stock Performance

Shares of NSPR opened at $2.50 on Friday. The firm has a market cap of $62.33 million, a price-to-earnings ratio of -3.29 and a beta of 0.96. InspireMD has a fifty-two week low of $1.81 and a fifty-two week high of $3.85. The firm has a 50 day moving average price of $2.48 and a 200-day moving average price of $2.52.

InspireMD (NYSE:NSPR) last announced its quarterly earnings data on Tuesday, May 14th. The company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.06). InspireMD had a negative return on equity of 55.12% and a negative net margin of 350.35%. The business had revenue of $1.51 million during the quarter, compared to the consensus estimate of $1.38 million. During the same quarter in the previous year, the firm posted ($0.53) earnings per share. As a group, equities research analysts predict that InspireMD will post -0.82 earnings per share for the current year.

Institutional Trading of InspireMD

A number of hedge funds and other institutional investors have recently modified their holdings of NSPR. McKinley Carter Wealth Services Inc. bought a new position in shares of InspireMD in the 4th quarter worth approximately $28,000. Mesirow Financial Investment Management Inc. bought a new stake in InspireMD in the first quarter worth $71,000. Finally, Rosalind Advisors Inc. lifted its position in InspireMD by 266.4% in the second quarter. Rosalind Advisors Inc. now owns 2,513,641 shares of the company’s stock worth $6,272,000 after buying an additional 1,827,579 shares during the last quarter. 44.78% of the stock is owned by hedge funds and other institutional investors.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.